New research suggests that individuals who discontinue popular GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who stop traditional lifestyle regimens.
Published data in a prominent medical journal demonstrates that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"Users using these treatments should be aware of the risk of quick rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to pre-treatment mass in about one and a half years.
Weighing Approaches
The research, which reviewed dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through lifestyle changes alone generally experience a more gradual creep back—around 100 grams monthly—after stopping.
Explaining the Fast Rebound
Doctors propose the mode of action of the drugs accounts for the amplified rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating a significant risk."
A Chronic Issue?
Health authorities recommend the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
A number of clinicians contend that, due to the significant potential of relapse, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who state that the findings "highlight the chronic character of obesity," akin to managing diseases like hypertension.
User Testimonies
People who have discontinued the jabs explain a intense resurgence of appetite.
"I experienced a trigger that goes on and you become ravenous," described one woman.
This difficulty is compounded if users have not established sustainable lifestyle or habit changes during treatment.
Widespread Interest
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among females than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while these medications are potent tools for shedding pounds, they are not a permanent fix and long-term success relies on ongoing lifestyle management.
